# ALNY Alnylam Pharmaceuticals Inc.: Hypertension Drug Zilebesiran Phase 2 Data Presentation
## Overview
### Company Profile
**Company Name:** Alnylam Pharmaceuticals Inc.
**Ticker:** ALNY
**Market Cap:** $35.41 Billion
**Stock Price:** $264.36 (Change: -$22.65, -7.89%)
**Relative Volume:** 129.95K
### Upcoming Catalyst
**Event:** European Society of Cardiology (ESC24) Congress
**Date:** August 30, 2024 – September 2, 2024
**Drug:** Zilebesiran
**Indication:** Hypertension
**Phase:** 2
**Study Name:** KARDIA-2
## Analysis
### Financial Metrics
1. **Cash Situation**
– Current: $17.69M
– Previous (January 25, 2023): $34.88M
– Change: -$17.19M
2. **Cash Expenditure**
– Quarterly Burn Rate: Approximately $2.32M
3. **Revenue and Liabilities**
– Revenue: $40,663,356
– Debt: $21.34M
### Importance for Investors
#### Mechanism of Action
Zilebesiran is a small interfering RNA (siRNA) therapeutic targeting liver-expressed angiotensinogen (AGT), critical in hypertension regulation.
#### Potential Market Impact
With a significant unmet need in hypertension management and the unique mechanism of zilebesiran, successful Phase 2 data can lead to substantial market uptake, further driving Alnylam’s valuation.
#### Previous Data
Earlier data (reported at the American College of Cardiology Scientific Sessions) indicated that zilebesiran showed clinically significant reductions in blood pressure, bolstering its potential.
### Upcoming Presentation
– **Conference:** European Society of Cardiology (ESC24) Congress on August 30, 2024.
– **Implications:** Positive data could serve as a strong catalyst for stock price appreciation, given days prior negative movement (Price Change: -7.89%).
## Investment Considerations
– **Positive Indicators:**
– Clinically significant Phase 2 results could lead to advancing to Phase 3 trials.
– Unmet need in hypertension treatment market.
– Previous promising data shared in academic forums.
– **Risks:**
– Cash burn rate and current financial reserves.
– Stock price volatility post-data release.
– Regulatory hurdles and competition in the market.
### Conclusion
Alnylam Pharmaceuticals’ upcoming ESC24 presentation on Zilebesiran marks a critical point for the company. Investors should closely monitor the outcome of this catalyst as significant positive data could offset the recent stock price decline and contribute to long-term stock value appreciation.
## Summary Table
| **Metric** | **Current Data** |
|—————————|——————–|
| Market Cap | $35.41 Billion |
| Stock Price | $264.36 (-7.89%) |
| Relative Volume | 129.95K |
| Cash Reserves | $17.69M |
| Quarterly Burn Rate | ~$2.32M |
| Revenue | $40.66 Million |
| Debt | $21.34 Million |
| Presentation Date | August 30, 2024 |
This upcoming event is a potential significant milestone for Alnylam Pharmaceuticals and should be watched closely by investors.